中国人群肝癌筛查指南

QE~$%&¾()$(hOhh,6) $"ß$g&'()* (2022,H,) !$1,#fi%1,ƒ'¾2,Ç*1,+,ffi1,./01,123,③Ⓒ4, 5ƒÇ5,¾9:6,;<7 =>?@gBCؾ‡GHÇJK =>?@gBCؾ‡GHfMK (1.!]#$%&/!]'()*“,.%&/%!“,/,ƒ1234“,ƒ'(“ƒ, 12100021;2.52“/],¿¾9N,ƒ/'(;<=“,>?¾@3№Bƒ%&,IE 52211166;3.12],¿¾9N,ƒ,12100191;4.ęG],$—“ƒ,ęGJK 130021;5.L$$“],3OP,QR,kL200433;6.UVW],“,?¿¾9N,ƒ, XY710061;7.Z[\]½P_`%&,abZ[518020) -.:%!ßdegghiNhj№¸lFjneop,®№$tu№ggvw¾yz[% !¿¾9N4]½P_|]~€??e?]??,?ggßd?$]??=[????? ?e???44??&%!ßdgg?$?5?!]9N???½?P?_|???, ?!]#$%&??,Ⓒę:,/Ç],g??9N????e?5????4??,?ę g#ßd?$]~e!??.ƒ½g,?➠%!!o??№??,??gg?$?№%e? $ßd¸?$??¸?ë??????½??,½?fi%!ßdgg?$?№e??????& /01:g'(;?$;?ë;?5;%! ChinaGuidelineforLiverCancerscreening(2022,Beijing) HEJie1,CHEN6an-qing1,SHENHong-bing2,LINi1,QUCkun-feng1,SHIJu-fang1,SUNFeng3,JIANGJing4,CAOGuang-wen5,ZHUANGGui-kua6,PENGJi7 ExpertGroupofCkinaGuidelineforLiverCancerScreening6orhingGroupofCkinaGuidelineforLiverCancerScreening (1.NationalCancerCenter/NationalClinicalResearckCenterforCancer/CancerHospital,CkineseAcademyofMedicalSciencesandPehingUnionMedicalCollege,Beijing100021,Ckina;2.SckoolofPublicHealtk,CollaborativeInnovationCenterforCancerPersonalizedMedicine,NanjingMedicalUniversity,Nanjing211166,Ckina;3.SckoolofPublicHealtk,PehingUniversity,Beijing,100191,Ckina;4.TkeFirstHospitalofJilinUniversity,Ckangckun130021,Ckina;5.DepartmentofEpidemiology,NavalMedicalUniversity,Skangkai200433,Ckina;6.SckoolofPublicHealtk,Xi'anJiaotongUniversityHealtkScienceCenter,Xi'an710061,Ckina;7.SkenzkenCenterforCkronicDiseaseControl,Skenzken518020,Ckina) Abstract:InCkina,tkesurvivalrateoflivercancerremainslowwkiletkemortalityrateiskigk.EffectivelyreducingtkeburdenoflivercancerisstillamajorckallengeintkefieldofpublickealtkandckronicdiseasepreventionamongtkeCkinesepopulation.Optimizingscreeningstrate-giesforlivercancerremainsaprofoundapproacktosecondarypreventionwortkyofcontinuousexploration.Toaddresstkispressingissue,tkeBureauofDiseaseControlandPreventionoftkeNationalHealtkCommissioncommissionedtkisguideline.TkeNationalCancerCenterofCkinainitiatedtkeguidelinedevelopmentandconvenedamultidisciplinaryexpertpanelandworhinggroups.Followingtke6orldHealtkOrganizationHandboohforGuidelineDevelopment,tkisguidelineintegratedtkemostup-to-dateevidenceoflivercancerscreening,Ckina'snationalcon-ditions,andexistingpracticalexperienceinlivercancerscreening.Evidence-basedrecommenda-tionsontketargetpopulation,screeningtecknologies,surveillancestrategies,andotkerheypointsacrosstkeprocessoflivercancerscreeningandsurveillancemanagementwereprovided.TkisguidelinewouldkelpstandardizetkepracticeoflivercancerscreeninginCkina. Keywords:liverneoplasms;screening;surveillance;guideline;Ckina NOQQ:2022–08–04 2g˛4R6¾№:—<= >?<=:2g,E-mail:kejie@cicams.ac.cn —˛"ę g"#$%a½ö½*+$—,2016.$%g"/0143F156fi38.989433.689,: ½/;43F;91<=fi>½?3@[1]$ABƒDEFgG;H(kepatitisBvirus,HBV)IJ¸KLMHNOⒸQJRBN?$TUV,WX1ƒ.$ %gZ/;[43F[\]^_`a[2],bgZc $5.Nf[g3ifi12.1%(2015.)[3]$jk, m$%gZno?pfirs.g3t▲vgZ¾x ?½z[2]$®№]—½$T_№$%g€?;¾x, g#$%¿¾?N4?½;?U???????? ]??$ $%gZ?$?2006.‡?Z?$?$???6?A??[4],g?????3?€?$? $??(2007.)4??€?$?$??(2012 .)??%]?]¿¾?N?????[5–10]$3?, ???M$€R?$?fi???€?,g€?$D g€3F[?^_T??D?№?f??,g€ ??$ß???[g?D?№[11],Bj,g€?$? ?g?ƒ?????$?ƒ?g€?$???4? ?½¸g€/N/??A½?g€?gRBN,mg€???№g3;?‰?ß??$????ß? ?ë??$ ½.?%?????:?g"?U????¾ ?,k?????“?½g???;???UVÇ ???½R?(?/½g"?5¾?$??ë?? (2020?))[12]¸??“?½g;?5½?(?/½g "?¾??¾?(2021.?))[13]½?▲%:??m ?½gZ$!?"?$?(PreCar)Ç]#? (?%gZ$?]%Ç]¾?)[14]R,fi$%gZ? U&'(???),*56&?(+?,?.4 ?????,fig???&/(??01$№3,$ 4??5??¾?*ƒ7?8??ę$½^]: ;DgZ—<??ß??=>?@$,???ß ?=>f?]6,:$DE«5?$4?ë?G3, ?$0I??$3JJK?)$]ª,NOPQ? ?NRS?ƒU½g?),?$XU?)$R$ fi(YZ(“[?%2030”]^_?)?`a ?½;?$4$!/]¸;D?/b«?AZ?? ?$?$?????c,d%]?N[??½? ;??UV?f,%]Z???gh#i:?j Ç]4???k,Zl%ƒ]n???Vo0p,qƒrƒ.½g4$%%t,?ƒ?Dmv,Vo(?%ß?gZ?$??(2022,wx))(½^yz (??)),½!fi$%ß?gZ?$?$?$??? ?]n??&/[?,&ƒ$%gZ?UT?$ $˛"%&#'()* l.%&Q,-./Ç$2(3:](??)V> d%]?N[??½?;??UV?f,~% ]Z???/$Ç]#??€?3?;?¸?½“ ?¸?NRS??].¸[??¸q?“?¸?? ???¸;??¸??/÷?“?¸kj?¸?j?R :?jÇ]$V>??ƒ2021.7$gffi,ƒ2022 .7$>?$ 2.%&4;672:?(??)??(:?j? ?#,€?k??????j?k$½g??4ƒU ~%]Z???¸wx]?“??¸?$$“]?¸ ę?]?$—“ƒ¸???]?“??ę???$ n$??#??<??(?‰???D,?f?? ](??)M???‰??$ 3.%&9:/;9<ƒß?:](??)?l ƒ5¾“???4????#i??gZ?$? ?$?(??)?l$k?b?ƒ5¾“??? gZ?$????“???$¸ß??$??] #i????$R$(??)?)7½?Zlƒß ?fi$71????dgZ?$?d?$$ 4.@ABCDE/F;:?WPQ??gZ? $??5/Q???¸¾?¸3??@ƒ½??5Ç ]??,??#??(kφ7]???????¾, €?+?????27?;?l???p½?n?? ????½,$1??§?¾??47ß?7½, ]—½?½??(??)????????25?$ 5.GHIJ:??V>??#??(½g?? ?ƒU?#,;Dr????????,??ß?¸ ç?¸D?4???]?@ƒ??,@ƒ1g?k ?PubMed¸Embase¸Clinicaltrial.org¸CockraneLi-brary¸NebofScience¸?%??¸80?????ę¸ ‰‰???4?%N?“?@ƒ1g?$jk,?? #*DgZ?$??3?¸?????@ƒ]??? !"#!½g"#&'0)fi2021+6$300! 6.!"ƒ$%&':½g"#-ƒ/012ƒ4567829:;(randomizedcontrolledtrial,RCT)=>?CockraneReviewer’sHandbooh5.0.1ƒ‰BCƒ/[15],2ƒ456DE=>?FƒHI–JKLMQBCƒ/[16],2ƒOP‰Q½= >?QUADAS-2BCƒ/[17],2ƒSTUE=> ?øWWXYZ[\=]ƒ/^_BCƒ/[18]!ƒ/`№b2cßXfg,hijk☞,m¾№pqr§t$÷wxy!?[|]½k¾6ƒ€¸? ??ƒ/(gradingofrecommendationsassessment,developmentandevaluation,GRADE)w?2½g?M4[|]½BCk¾[19](Q1)! 7.()*+,-:Ç]1?ƒ½g"#-ƒ/ 01??6W??½g,№??ƒ?W?$ƒß ?6??4/??¸ç???6g?4?g,?½ ???g??$????6[|]½!2022+2—3 $???ƒ—??